MAO-B Imaging Probe With Tau-Free Binding for Astrocyte Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic imaging methods for neurological diseases, such as Parkinson's disease and Amyotrophic Lateral Sclerosis, lack a probe that selectively binds to monoamine oxidase-B (MAO-B) without binding to misfolding proteins like tau, limiting accurate diagnosis and quantification of astrocytes.
Innovation Solution
Development of a compound represented by formula (I) with high specificity and selectivity for MAO-B, which does not bind to tau, enabling sensitive MAO-B imaging and quantification of astrocytes, along with a precursor compound represented by formula (II) for its synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a compound is designed to bind to tau protein for diagnostic imaging, then tau detection capability is improved, but binding specificity to monoamine oxidase-B deteriorates
Solution Approach 1:
The invention extracts and removes the tau-binding property from the imaging compound while retaining the monoamine oxidase-B binding capability. By modifying the chemical structure of THK-5351 to create THK-5470, the compound selectively loses affinity for tau protein while maintaining high affinity for monoamine oxidase-B, thereby resolving the contradiction between tau detection and MAO-B specificity.
2Adaptability or versatility
If a compound shows high affinity to both tau and monoamine oxidase-B, then imaging coverage is improved, but diagnostic accuracy for monoamine oxidase-B deteriorates
Solution Approach 1:
The invention selectively removes the non-specific binding property to tau protein while preserving the specific binding to monoamine oxidase-B. This extraction of unwanted binding affinity ensures that the compound provides accurate diagnostic imaging for monoamine oxidase-B related diseases without the confounding effect of tau binding.
Solution Approach 2:
The invention changes the chemical parameters of the imaging compound by modifying the molecular structure (changing from THK-5351 to THK-5470). This structural modification alters the binding parameters, reducing affinity for tau protein while maintaining or enhancing affinity for monoamine oxidase-B, thereby improving diagnostic accuracy.
3Measurement precision
If a probe is developed for specific neurological diseases, then disease-specific diagnosis is improved, but applicability to other neurological diseases deteriorates
Solution Approach 1:
The invention creates a universal imaging probe (THK-5470) that targets monoamine oxidase-B, an enzyme expressed in astrocytes that are involved in multiple neurological diseases. By targeting this common pathological feature rather than disease-specific markers, the compound achieves broad applicability across various neurological conditions including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Data Source
AI summary
The present invention provides a compound represented by formula (I) that can image monoamine oxidase-B with high specificity and selectivity for monoamine oxidase-B and with good sensitivity, or a pharmaceutically acceptable salt or solvate thereof.